PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Tesamorelin: Research & Evidence

Established Evidence

Published research, clinical trial data, and evidence grading for Tesamorelin across studied indications.

Back to Tesamorelin overview

Research Summary

Tesamorelin is backed by two pivotal Phase 3 trials (N=816) demonstrating significant visceral fat reduction, with 52-week and 104-week extension data confirming sustained efficacy. It is the first and only FDA-approved treatment for HIV-associated lipodystrophy.

Evidence by Indication (4 indications)

Indication Tier Trials Summary
HIV-associated lipodystrophy Tier A 5 FDA-approved indication — reduces trunk fat by 15-18% in pivotal trials
Body composition (non-HIV) Tier B 3 Reduces visceral adipose tissue and improves lipid profiles in non-HIV populations
Cognitive function (MCI) Tier C 1 Phase II trial showed improved executive function in adults with mild cognitive impairment
NAFLD/Fatty liver disease Tier C 1 Limited data showing potential benefit in non-alcoholic fatty liver disease

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (11 sources)

  1. 1. Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study. Study

    (2025), Cureus

  2. 2. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. Study

    (2024), AIDS (London, England)

  3. 3. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Clinical Trial

    (2019), The lancet. HIV

  4. 4. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes. Clinical Trial

    (2017), PloS one

  5. 5. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. Review

    (2017), BMC infectious diseases

  6. 6. Predictors of Treatment Response to Tesamorelin in HIV-Infected Patients with Excess Abdominal Fat. Study

    (2015), PloS one

  7. 7. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Study

    (2012), The Annals of pharmacotherapy

  8. 8. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Review

    (2011), Drugs

  9. 9. Spotlight on tesamorelin in HIV-associated lipodystrophy. Study

    (2011), BioDrugs

  10. 10. Pathogenesis and treatment of HIV lipohypertrophy. Study

    (2011), Current opinion in infectious diseases

  11. 11. Tesamorelin Phase 3 Study 001 for HIV-associated lipodystrophy. Clinical Trial

    (2010), Various